Organization
Oric Pharmaceuticals
6 clinical trials
Clinical trial
An Open-label Phase 1b Study of ORIC-101 in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid TumorsStatus: Terminated, Estimated PCD: 2022-09-22
Clinical trial
A Phase 1, Randomized, Open-Label, Crossover Study Evaluating the Effect of Food on the Pharmacokinetics of ORIC-114 Tablet Formulation in Healthy SubjectsStatus: Completed, Estimated PCD: 2023-11-23
Clinical trial
An Open-Label Phase 1b Study of ORIC-101 in Combination With Enzalutamide in Patients With Metastatic Prostate Cancer Progressing on EnzalutamideStatus: Terminated, Estimated PCD: 2022-11-22
Clinical trial
An Open-Label, Phase 1/1b, Study of ORIC-944 in Patients With Metastatic Prostate CancerStatus: Recruiting, Estimated PCD: 2023-05-01
Clinical trial
An Open-label Phase 1b Study of ORIC-533 in Patients With Relapsed or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 AlterationStatus: Recruiting, Estimated PCD: 2025-03-01